Alexion strikes another anti-FcRn deal, bagging Affibody drug

ludwig hantson
Alexion CEO Ludwig Hantson. (Alexion)

Alexion has paid Affibody $25 million (€22 million) to co-develop a treatment for rare IgG-mediated autoimmune diseases. The deal gives Alexion rights to an anti-FcRn drug designed to have a longer half-life than rival assets in development at Argenx, UCB and other companies.

Rare disease specialist Alexion bought its way into the race to bring an anti-FcRn antibody to market last year when it paid $400 million to acquire Syntimmune. That deal gave Alexion control of STNT001, a midphase asset jostling with Argenx’s efgartigimod and UCB’s rozanolixizumab toward the front of the FcRn race.

Now, Alexion has picked up rights to an earlier-phase asset designed to improve on the frontrunners, Affibody’s ABY-039. While other anti-FcRn drugs are monoclonal antibodies or antibody fragments, ABY-039 is an antibody mimetic. Such drugs specifically bind antigens, like antibodies do, but have a different structure than the better-known modality. Notably, ABY-039 is far smaller than a typical antibody, coming in at 18 kDa. IgG antibodies have molecular weights of around 150 kDa.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

In the case of ABY-039, Alexion thinks the antibody mimetic modality has resulted  in a drug that has a longer half life than antibodies directed at FcRn and can be delivered via low-volume subcutaneous administration. Those features could give ABY-039 an edge over other anti-FcRn drugs, including Alexion’s STNT001, now known as ALXN1830.

Alexion has neutralized the threat posed by ABY-039 by paying $25 million upfront and committing to up to $625 million in development and sales-based milestones. The deal will see Alexion lead joint clinical development and commercialization. Affibody has retained an option to co-promote the drug in the U.S. and lead clinical development in an undisclosed location. 

Affibody moved ABY-039 into a phase 1 study in healthy volunteers last year to assess its safety, tolerability and pharmacokinetics. The trial is evaluating intravenous and subcutaneous formulations of ABY-039. 

Beyond that, a range of opportunities for further development could open up. FcRn extends the half-life of IgG antibodies, including molecules that promote autoimmune disease. Disrupting  interactions between FcRn and IgG could therefore accelerate the clearance of these disease-causing autoantibodies, thereby improving outcomes in a range of autoimmune diseases.

ALXN1830 is in development in indications including pemphigus and warm autoimmune hemolytic anemia, while Argenx and UCB are testing their drugs in myasthenia gravis.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.